These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 33691325)

  • 1. Treatment of Essential Thrombocythemia with Anagrelide Is Associated with an Increased Risk of Worsened Kidney Function.
    Kwiatkowski J; Kuliszkiewicz-Janus M; Rymer W; Jaźwiec B; Małecki R
    Pharmacology; 2021; 106(5-6):316-322. PubMed ID: 33691325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anagrelide and Mutational Status in Essential Thrombocythemia.
    Iurlo A; Cattaneo D; Orofino N; Bucelli C; Fabris S; Cortelezzi A
    BioDrugs; 2016 Jun; 30(3):219-23. PubMed ID: 27041108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.
    Mela Osorio MJ; Ferrari L; Goette NP; Gutierrez MI; Glembotsky AC; Maldonado AC; Lev PR; Alvarez C; Korin L; Marta RF; Molinas FC; Heller PG
    Eur J Haematol; 2016 Apr; 96(4):435-42. PubMed ID: 26119186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study.
    Cascavilla N; De Stefano V; Pane F; Pancrazzi A; Iurlo A; Gobbi M; Palandri F; Specchia G; Liberati AM; D'Adda M; Gaidano G; Fjerza R; Achenbach H; Smith J; Wilde P; Vannucchi AM
    Drug Des Devel Ther; 2015; 9():2687-94. PubMed ID: 26028965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
    Iványi JL; Marton É; Plander M; Szendrei T
    Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting.
    Ito T; Hashimoto Y; Tanaka Y; Nakaya A; Fujita S; Satake A; Nakanishi T; Konishi A; Hotta M; Yoshimura H; Ishii K; Hashimoto A; Kondo T; Omura H; Shinzato I; Tanaka T; Nomura S
    Eur J Haematol; 2019 Aug; 103(2):116-123. PubMed ID: 31107982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Observational retrospective study of vascular modulator changes during treatment in essential thrombocythemia.
    Piccin A; Steurer M; Feistritzer C; Murphy C; Eakins E; Van Schilfgaarde M; Corvetta D; Di Pierro AM; Pusceddu I; Marcheselli L; Gambato R; Langes M; Veneri D; Perbellini O; Pacquola E; Gottardi M; Gherlinzoni F; Mega A; Tauber M; Mazzoleni G; Piva E; Plebani M; Krampera M; Gastl G
    Transl Res; 2017 Jun; 184():21-34. PubMed ID: 28259616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study.
    Gugliotta L; Besses C; Griesshammer M; Harrison C; Kiladjian JJ; Coll R; Smith J; Abhyankar B; Birgegård G
    Haematologica; 2014 Apr; 99(4):679-87. PubMed ID: 24334294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia.
    Birgegård G
    Curr Hematol Malig Rep; 2016 Oct; 11(5):348-55. PubMed ID: 27497846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
    Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
    N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide.
    Tefferi A; Szuber N; Vallapureddy RR; Begna KH; Patnaik MM; Elliott MA; Christopher Hook C; Wolanskyj AP; Hanson CA; Ketterling RP; Pardanani A; Gangat N
    Am J Hematol; 2019 Jan; 94(1):5-9. PubMed ID: 30252953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia.
    Alvarez-Larrán A; Angona A; Andrade-Campos M; Soledad Noya M; Teresa Gómez-Casares M; Cuevas B; Caballero G; García-Hernández C; García-Gutiérrez V; Palomino A; Ferrer-Marín F; Isabel Mata-Vázquez M; Moretó A; Magro E; Murillo I; Manuel Alonso-Domínguez J; María Guerra J; Guerrero L; María Raya J; Pérez-Encinas M; Carreño-Tarragona G; Fox L; Pastor-Galán I; Bellosillo B; Hernández-Boluda JC;
    Br J Haematol; 2021 Mar; 192(6):988-996. PubMed ID: 32745264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
    Rey J; Viallard JF; Keddad K; Smith J; Wilde P; Kiladjian JJ;
    Eur J Haematol; 2014 Feb; 92(2):127-36. PubMed ID: 24118452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: correlation with JAK2V617F mutational status and cytoreductive therapy.
    Treliński J; Chojnowski K; Cebula-Obrzut B; Smolewski P
    Med Oncol; 2012 Dec; 29(4):2388-95. PubMed ID: 22418850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis.
    Mesquita Mdo C; Sol EB; Malarme M; Noubouossie D; Demulder AC
    Clin Ther; 2009 Nov; 31(11):2559-64. PubMed ID: 20110000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anagrelide and the CALR mutation allele burden in essential thrombocythemia.
    Atkinson E; Bakri M; Hayat A; Langabeer SE
    Exp Oncol; 2018 Jun; 40(2):152-153. PubMed ID: 29949532
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged >80 years: an interim analysis of the EXELS study.
    Kiladjian JJ; Besses C; Griesshammer M; Gugliotta L; Harrison C; Coll R; Smith J; Birgegård G
    Clin Drug Investig; 2013 Jan; 33(1):55-63. PubMed ID: 23184668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Evaluation of the Efficacy and Safety of Anagrelide Used with or without Hydroxycarbamide in Japanese Patients with Essential Thrombocythemia-A Retrospective Single-Center Study of 35 Cases.
    Sekiguchi Y; Wakabayashi M; Takizawa H; Iizuka H; Sakajiri S; Sugimoto K; Inano T; Fukuda Y; Hamano Y; Tomita S; Izumi H; Okubo M; Nakamura N; Sawada T; Noguchi M
    Gan To Kagaku Ryoho; 2019 Jul; 46(7):1141-1150. PubMed ID: 31296820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anagrelide in the treatment of thrombocythemia essential (ET)].
    Mazur G; Wróbel T; Podolak-Dawidziak M; Kuliszkiewicz-Janus M; Potoczek S; Nosol J; Kuliczkowski K
    Pol Arch Med Wewn; 2004 Dec; 112(6):1445-50. PubMed ID: 15962609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anagrelide: new drug. Essential thrombocythaemia: further evaluation needed for this last-resort treatment.
    Prescrire Int; 2006 Jun; 15(83):83-6. PubMed ID: 16764090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.